|
US6642268B2
(en)
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
|
US6262277B1
(en)
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
GB9423172D0
(en)
*
|
1994-11-17 |
1995-01-04 |
Wellcom Foundation The Limited |
Hypolipidemic benzothiazepines
|
|
US6221897B1
(en)
|
1998-06-10 |
2001-04-24 |
Aventis Pharma Deutschland Gmbh |
Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
|
|
EP1293211A1
(fr)
*
|
1998-12-23 |
2003-03-19 |
G.D. Searle LLC. |
Combinaisons d'inhibiteurs de transport de l'acide biliaire iléal et agents séquestrants l'acide biliaire pour indications cardiovasculaires
|
|
WO2000038721A1
(fr)
|
1998-12-23 |
2000-07-06 |
G.D. Searle Llc |
Combinaisons d'inhibiteurs de la proteine de transfert du cholesteryle-ester et de derives de l'acide nicotinique utilisees dans le cadre de troubles cardio-vasculaires
|
|
WO2000038727A1
(fr)
*
|
1998-12-23 |
2000-07-06 |
G.D. Searle Llc |
Combinaisons d'inhibiteurs de transport de l'acide biliaire ileal et de derives de l'acide fibrique utilisees dans le cadre de maladies cardio-vasculaires
|
|
JP2002536440A
(ja)
*
|
1999-02-12 |
2002-10-29 |
ジー.ディー.サール エルエルシー |
回腸胆汁酸輸送およびタウロコール酸塩取り込みの阻害剤としての活性を有する新規1,2−ベンゾチアゼピン
|
|
SE0000772D0
(sv)
|
2000-03-08 |
2000-03-08 |
Astrazeneca Ab |
Chemical compounds
|
|
SE0003766D0
(sv)
*
|
2000-10-18 |
2000-10-18 |
Astrazeneca Ab |
Novel formulation
|
|
EG26979A
(en)
|
2000-12-21 |
2015-03-01 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0121337D0
(en)
|
2001-09-04 |
2001-10-24 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0121621D0
(en)
|
2001-09-07 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0121622D0
(en)
|
2001-09-07 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
|
AU2002329387B2
(en)
*
|
2001-09-08 |
2007-06-07 |
Albireo Ab |
Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (IBAT) inhibitory activity for the treatment hyperlipidaemia
|
|
US6852753B2
(en)
|
2002-01-17 |
2005-02-08 |
Pharmacia Corporation |
Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
|
|
GB0209467D0
(en)
*
|
2002-04-25 |
2002-06-05 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0213669D0
(en)
|
2002-06-14 |
2002-07-24 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0304194D0
(en)
|
2003-02-25 |
2003-03-26 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0307918D0
(en)
|
2003-04-05 |
2003-05-14 |
Astrazeneca Ab |
Therapeutic use
|
|
US20100048950A1
(en)
*
|
2007-04-10 |
2010-02-25 |
Boehringer Ingelheim International Gmbh |
Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof
|
|
WO2010062861A2
(fr)
*
|
2008-11-26 |
2010-06-03 |
Satiogen Pharmaceuticals, Inc. |
Inhibiteurs de recyclage de l'acide biliaire pour le traitement de l'obésité et du diabète
|
|
ES2552657T3
(es)
|
2010-05-26 |
2015-12-01 |
Satiogen Pharmaceuticals, Inc. |
Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
|
|
ES2687027T3
(es)
|
2010-11-04 |
2018-10-23 |
Albireo Ab |
Inhibidores de ibat para el tratamiento de enfermedades hepáticas
|
|
US20130108573A1
(en)
|
2011-10-28 |
2013-05-02 |
Lumena Pharmaceuticals, Inc. |
Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
|
|
AU2012328526B2
(en)
|
2011-10-28 |
2017-05-25 |
Shire Human Genetic Therapies, Inc. |
Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
|
|
AU2014229050A1
(en)
|
2013-03-15 |
2015-10-22 |
Lumena Pharmaceuticals Llc |
Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
|
|
CA2907230A1
(fr)
|
2013-03-15 |
2014-09-18 |
Lumena Pharmaceuticals, Inc. |
Inhibiteurs du recyclage de l'acide biliaire pour le traitement de l'angiocholite sclerosante primaire et de la maladie inflammatoire de l'intestin
|
|
JO3301B1
(ar)
|
2013-04-26 |
2018-09-16 |
Albireo Ab |
تعديلات بلورية على إيلوبيكسيبات
|
|
CN106659726A
(zh)
|
2014-06-25 |
2017-05-10 |
Ea制药株式会社 |
固体制剂及其着色防止或着色减少方法
|
|
EP3012252A1
(fr)
|
2014-10-24 |
2016-04-27 |
Ferring BV |
Formes crystallines d'Elobixibat
|
|
CN108601739B
(zh)
|
2016-02-09 |
2022-01-04 |
阿尔比里奥公司 |
考来烯胺丸剂及其制备方法
|
|
ES2874669T3
(es)
|
2016-02-09 |
2021-11-05 |
Albireo Ab |
Formulación oral de colestiramina y uso de la misma
|
|
WO2017138878A1
(fr)
|
2016-02-09 |
2017-08-17 |
Albireo Ab |
Formulation orale de cholestyramine et utilisation associée
|
|
CN111032019B
(zh)
|
2017-08-09 |
2022-07-05 |
阿尔比里奥公司 |
考来烯胺颗粒、口服考来烯胺制剂及其用途
|
|
CN112449637B
(zh)
|
2018-06-05 |
2024-03-19 |
阿尔比里奥公司 |
苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
|
|
US11801226B2
(en)
|
2018-06-20 |
2023-10-31 |
Albireo Ab |
Pharmaceutical formulation of odevixibat
|
|
PL3810581T3
(pl)
|
2018-06-20 |
2025-04-28 |
Albireo Ab |
Modyfikacje kryształu odewiksibatu
|
|
US11007142B2
(en)
|
2018-08-09 |
2021-05-18 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
US11549878B2
(en)
|
2018-08-09 |
2023-01-10 |
Albireo Ab |
In vitro method for determining the adsorbing capacity of an insoluble adsorbant
|
|
US10722457B2
(en)
|
2018-08-09 |
2020-07-28 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
CN118852054A
(zh)
*
|
2019-02-06 |
2024-10-29 |
阿尔比里奥公司 |
苯并硫杂二氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
|
|
TWI835997B
(zh)
|
2019-02-06 |
2024-03-21 |
瑞典商艾爾比瑞歐公司 |
苯并噻氮呯化合物及其用作膽酸調節劑之用途
|
|
EP3923943B1
(fr)
|
2019-02-12 |
2024-07-31 |
Mirum Pharmaceuticals, Inc. |
Réponse dépendant du génotype et de la dose à un asbti chez des patients ayant une déficience de pompe d'exportation de sel biliaire
|
|
CN111808045B
(zh)
*
|
2019-04-12 |
2022-07-08 |
中国科学院大连化学物理研究所 |
一种有机催化合成手性七元环状磺胺的方法
|
|
TWI877263B
(zh)
*
|
2019-12-04 |
2025-03-21 |
瑞典商艾爾比瑞歐公司 |
苯并噻二氮呯化合物及其作為膽酸調節劑之用途
|
|
ES2973355T3
(es)
|
2019-12-04 |
2024-06-19 |
Albireo Ab |
Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
|
|
JP7696898B2
(ja)
|
2019-12-04 |
2025-06-23 |
アルビレオ・アクチボラグ |
ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
|
|
EP4069247B1
(fr)
|
2019-12-04 |
2025-03-26 |
Albireo AB |
Composés de benzothiadiazépine et leur utilisation en tant que modulateurs de l'acide biliaire
|
|
US11014898B1
(en)
|
2020-12-04 |
2021-05-25 |
Albireo Ab |
Benzothiazepine compounds and their use as bile acid modulators
|
|
IL293379B2
(en)
|
2019-12-04 |
2026-04-01 |
Albireo Ab |
Benzothia(dia)azepine compounds and their use as bile acid modulators
|
|
EP4188541B1
(fr)
|
2020-08-03 |
2024-12-25 |
Albireo AB |
Composés de benzothia(di)azepine et leur utilisation en tant que modulateurs de l'acide biliaire
|
|
CA3196488A1
(fr)
|
2020-11-12 |
2022-05-19 |
Albireo Ab |
Odevixibat pour le traitement de la cholestase intrahepatique familiale progressive (cifp)
|
|
BR112023010799A2
(pt)
|
2020-12-04 |
2023-10-03 |
Albireo Ab |
Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares
|
|
TW202313579A
(zh)
|
2021-06-03 |
2023-04-01 |
瑞典商艾爾比瑞歐公司 |
苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
|